• About Us
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Respiratory and Acute Care Advisory Board
  • Cardiovascular Advisory Board
  • Immunology Advisory Board
  • Investors
• Products
• Research
  • sPLA2 - What is it?
  • Respiratory and Acute Care Program
  • sPLA2 in SCD
  • IMPACTS Trial Site
  • Scientific Advisory Board
  • Cardiovascular Program
  • sPLA2 in CVD
  • FRANCIS Trial Site
  • PLASMA Trial Site
  • PLASMA 2 Trial Site
  • Scientific Advisory Board
  • Immunology Program
  • A-623 in SLE and Autoimmune Diseases
  • Scientific Advisory Board
  • Preclinical Programs
  • Glossary
  • References
• News & Media
• Careers
• Contact Us

<< Return to Board of Directors

Rachel Leheny‚ Managing Director, Caxton Advantage Life Sciences Fund

In 2004, Dr. Leheny co-founded as the Managing General Partner of the Caxton Advantage Life Sciences Fund. From 2000 to 2002, she was the Head of the Biotechnology Research Team and a Senior Vice President at Lehman Brothers. Prior to Lehman Brothers, Dr. Leheny headed the Biotechnology Research Team at UBS Warburg which she joined as an Executive Vice President in early 1998. From 1993 to 1998, Dr. Leheny worked at Hambrecht & Quist, most recently as a Managing Director and Senior Biotechnology Analyst. Dr. Leheny was named a Wall Street Journal Research All-Star for stock picking in 1996, 1998, 2002.

Dr. Leheny obtained her A.B. in chemistry with honors from Harvard College in 1985. She received a Ph.D. in chemistry from Columbia University in 1991 and did post-doctoral work at the University of California, Berkeley, in 1992-93. At Berkeley, she was also an NIH fellow and a lecturer in the Department of Chemistry.